Neutralization Profiles of Newly Transmitted Human Immunodeficiency Virus Type 1 by Monoclonal Antibodies 2G12, 2F5, and 4E10-Reference-Cited by-同舟云学术

Neutralization Profiles of Newly Transmitted Human Immunodeficiency Virus Type 1 by Monoclonal Antibodies 2G12, 2F5, and 4E10

Published:2004-12-15 Issue:24 Volume:78 Page:14039-14042
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Mehandru Saurabh¹,Wrin Terri²,Galovich Justin²,Stiegler Gabriela³,Vcelar Brigitta³,Hurley Arlene¹,Hogan Christine¹,Vasan Sandhya¹,Katinger Hermann³,Petropoulos Christos J.²,Markowitz Martin¹

Affiliation:

1. Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York

2. ViroLogic, Inc., South San Francisco, California

3. Polymun Scientific, Vienna, Austria

Abstract

ABSTRACT As the AIDS epidemic continues unabated, the development of a human immunodeficiency virus (HIV) vaccine is critical. Ideally, an effective vaccine should elicit cell-mediated and neutralizing humoral immune responses. We have determined the in vitro susceptibility profile of sexually transmitted viruses from 91 patients with acute and early HIV-1 infection to three monoclonal antibodies, 2G12, 2F5, and 4E10. Using a recombinant virus assay to measure neutralization, we found all transmitted viruses were neutralized by 4E10, 80% were neutralized by 2F5, and only 37% were neutralized by 2G12. We propose that the induction of 4E10-like antibodies should be a priority in designing immunogens to prevent HIV-1 infection.

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.78.24.14039-14042.2004

Reference27 articles.

1. Armbruster, C., G. M. Stiegler, B. A. Vcelar, W. Jager, N. L. Michael, N. Vetter, and H. W. Katinger. 2002. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS16:227-233.

2. HIV vaccine design and the neutralizing antibody problem

3. Calarese, D. A., C. N. Scanlan, M. B. Zwick, S. Deechongkit, Y. Mimura, R. Kunert, P. Zhu, M. R. Wormald, R. L. Stanfield, K. H. Roux, J. W. Kelly, P. M. Rudd, R. A. Dwek, H. Katinger, D. R. Burton, and I. A. Wilson. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science300:2065-2071.

4. Cardosa R. M. B. Zwick R. Kunert H. Katinger D. R. Burton and I. A. Wilson. 2003. Structural insights for 4E10 antibody neutralization on HIV-1. AIDS Vaccine 2003 New York N.Y. [Online.] http://www.aidsvaccine2003.org .

5. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention;Viruses;2024-06-04

2. Antibody response against selected epitopes in the HIV-1 envelope gp41 ectodomain contributes to reduce viral burden in HIV-1 infected patients;Scientific Reports;2021-04-26

3. Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies;Virus Research;2018-01

4. Characterization of Humoral Immune Responses against Capsid Protein p24 and Transmembrane Glycoprotein gp41 of Human Immunodeficiency Virus Type 1 in China;PLOS ONE;2016-11-01

5. Impact of early cART in the gut during acute HIV infection;JCI Insight;2016-07-07